Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine for Cognitive Decline in Down Syndrome
NCT01778946Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2013
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nicotine in Mild Cognitive Impairment (MCI), sponsored by Vanderbilt University Medical Center. Primary endpoint: Tolerability of Nicotine Intervention at 1 month. Started Apr 2013; status: completed.
02
Drugs
nicotine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01778946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01778946.